

1 **Mutation of *kvrA* causes OmpK35/36 porin downregulation and reduced**
 2 **meropenem/vaborbactam susceptibility in KPC-producing *Klebsiella pneumoniae*.**

3

4

5 **Punyawee Dulyayangkul^a, Wan Ahmad Kamil Wan Nur Ismah^{a,b}, Edward J. A.**
 6 **Douglas^a, Matthew B. Avison^{a#}**

7

8

9 **^aSchool of Cellular & Molecular Medicine, University of Bristol, Bristol. UK**

10 **^bFaculty of Biotechnology & Biomolecular Sciences, Universiti Putra Malaysia,**
 11 **Selangor Darul Ehsan, Malaysia.**

12

13

14 **#Correspondence to: School of Cellular & Molecular Medicine, University of Bristol,**
 15 **Bristol, United Kingdom. bimba@bris.ac.uk**

16

17 **P.D. and W.A.K.W.N.I. contributed equally to this work.**

18

19

20 **Running Title: KvrA loss reduces porin production in *K. pneumoniae***

21 **Abstract**

22 **Meropenem/vaborbactam resistance in *Klebsiella pneumoniae* is associated with loss**
 23 **of function mutations in the OmpK36 porin. Here we identify two previously unknown**
 24 **loss of function mutations that confer cefuroxime resistance in *K. pneumoniae*. The**
 25 **proteins lost were NlpD and KvrA; the latter is a transcriptional repressor that**
 26 **controls capsule production. We demonstrate that KvrA loss reduces OmpK35 and**
 27 **OmpK36 porin production, which confers reduced susceptibility to**
 28 **meropenem/vaborbactam in a KPC-3 producing *K. pneumoniae* clinical isolate.**

29 Text

30 Carbapenems are often reserved as a last resort for treatment of severe infections caused
 31 by multi-drug resistant Gram-negative bacteria. A rise in the prevalence of cephalosporin
 32 resistance, particularly due to the spread of mobile cephalosporinase genes in the
 33 Enterobacteriaceae has resulted in the increased use of carbapenems worldwide. This has
 34 driven the emergence of carbapenem resistant Enterobacteriaceae (CRE) which are classed
 35 as one of the greatest threats to human health according to the World Health Organisation.
 36 In *Klebsiella pneumoniae*, carbapenem resistance is mainly mediated by the production of a
 37 carbapenemase. In some parts of the world the most prevalent is the class A
 38 carbapenemase KPC; in others, most common are the class B metallo- β -lactamases e.g.
 39 NDM; in others, most class D carbapenemases e.g. OXA-48 like enzymes predominate (1-
 40 3). CRE can also emerge due to mutations that reduce envelope permeability, for example
 41 those that result in porin deficiency, and particularly when these mutations occur in isolates
 42 producing CTX-M or AmpC-type cephalosporinases (4). Indeed, most carbapenem resistant
 43 *K. pneumoniae* clinical isolates have multiple resistance mechanisms, including permeability
 44 defects (5-8).

45 As part of our work aiming to identify novel mechanisms for reduced cephalosporin and/or
 46 carbapenem permeability in *K. pneumoniae*, the *oqxR* and *ramR* double mutant, FQ3,
 47 derived from *K. pneumoniae* Ecl8 as previously described (9) was used as a parent strain to
 48 select cephalosporin resistant mutants. FQ3 overproduces two efflux pumps; AcrAB and
 49 OqxAB, resulting in resistance to fluoroquinolones, chloramphenicol and minocycline (9).
 50 One hundred microlitre aliquots of overnight cultures grown in Nutrient Broth (NB) were
 51 spread onto Mueller Hinton Agar containing $16 \mu\text{g.mL}^{-1}$ cefuroxime, which were then
 52 incubated for 24 h. One representative mutant derivative was named "FQ3 M1" and was
 53 shown by disc susceptibility testing, performed and interpreted according to CLSI
 54 methodology (10, 11) to be resistant to cefuroxime, cefoxitin and cephalixin (**Table 1**).

55 Changes in envelope protein abundance in mutant FQ3 M1 relative to FQ3 were quantified
 56 using LC-MS/MS proteomics as previously described (9) to identify potential reasons for
 57 cephalosporin resistance. There were 15 proteins significantly altered (**Table 2**). Amongst
 58 this group of proteins with uncertain or metabolic functions, were the important antimicrobial
 59 entry porins OmpK35 and OmpK36, which were both downregulated in FQ3 M1 by almost 3-
 60 fold.

61 We next used WGS to try and explain the downregulation of OmpK35 and OmpK36 in
 62 mutant FQ3 M1 relative to FQ3. WGS was performed by MicrobesNG (Birmingham, UK)
 63 using a HiSeq 2500 instrument (Illumina, San Diego, CA, USA). Reads were trimmed using

64 Trimmomatic (12) and assembled into contigs using SPAdes 3.10.1
65 (<http://cab.spbu.ru/software/spades/>). Assembled contigs were mapped to the *K.*
66 *pneumoniae* Ecl8 reference genome (GenBank accession number GCF_000315385.1) by
67 using progressive Mauve alignment software (13).

68 No mutations were detected in *ompK36* and *ompK35* or adjacent sequences, or in known
69 regulators of porin production, e.g. OmpR/EnvZ (14). In fact, FQ3 M1 has three separate
70 mutations relative to FQ3: a frameshift mutation (causing Asn278FS) in *nlpD*, a frameshift
71 (causing Asp395FS) in *dhaR*, and a 1,159 bp deletion spanning *kvrA* and the adjacent
72 genes, *ydhl* and *ydjJ*. In *Escherichia coli*, NlpD is involved in peptidoglycan remodelling
73 during cell division (15-17). DhaR is a transcriptional activator responsible for controlling the
74 production of the metabolic enzymes glycerol dehydrogenase and dihydroxyacetone kinase
75 (18,19). KvrA is a MarR-type transcriptional repressor with a key role in *K. pneumoniae*
76 capsulation (20-22).

77 In order to deconvolute the possible roles of the three different loss of function mutations, we
78 separately insertionally inactivated *nlpD*, *dhaR* and *kvrA*, plus *ompK36* as controls in FQ3.
79 Mutants were constructed using the pKNOCK suicide plasmid (23). DNA fragments of the
80 genes to be inactivated were amplified with Phusion High-Fidelity DNA Polymerase (NEB,
81 UK) from *K. pneumoniae* Ecl8 genomic DNA by using primers *ompK36* KO FW (5'-
82 CGTTCAGGCGAACAACACTG-3') and *ompK36* KO RV (5'-AAGTTCAGGCCGTCAACCAG-
83 3'); *kvrA* KO FW (5'-ATCTGGCACGTTTAGTTTCGC-3') and *kvrA* KO RV (5'-
84 CCCTTCTCCTCCAGCTGAT-3'); *dhaR* KO FW (5'-CAATCAGATGTACGGCCTGC-3') and
85 *dhaR* KO RV (5'-GACTTCGACGTGATTCAGGC-3'); *nlpD* KO FW (5'-
86 ACGATTTCCGCGACCTGGCG-3') and *nlpD* KO RV (5'-CAACATCTTGGTAGCACTCT-3').
87 Each PCR product was separately ligated into the pKNOCK-GM at the *Sma*I site and each
88 recombinant plasmid was then transferred into FQ3 cells by conjugation from *E. coli*
89 BW20767. Mutants were selected using gentamicin (5 µg.mL⁻¹) and the mutations were
90 confirmed by PCR using primers *ompK36* full length FW (5'-GAGGCATCCGGTTGAAATAG-
91 3') and *ompK36* full length RV (5'-ATTAATCGAGGCTCCTCTTAC-3'); *kvrA* full length FW
92 (5'-ACTTAGCAAGCTAATTATAAGGAGATGA-3') and *kvrA* full length RV (5'-
93 GCCGCAAAGAATTAATCTTTA-3'); *dhaR* full length FW (5'-CAGCCCGATGGACGAGATT-
94 3') and *dhaR* full length RV (5'-TATTGGGCTCAGCGCGTCC-3'); *nlpD* full length FW (5'-
95 GTCGGCGAAGAGCATCAGT-3') and *nlpD* full length RV (5'-CACCTTCCACGGCACATCA-
96 3').

97 Inactivating *dhaR* in FQ3 had no effect on cephalosporin MIC, determined using CLSI
98 methodology (24) but inactivating *nlpD* or *kvrA*, raised cefoxitin and cefuroxime MIC, though

in both cases the MIC was one doubling lower than against FQ3 M1 (**Table 3**). We next complemented *kvrA* in FQ3 M1. To do this, *kvrA* DNA was amplified from *K. pneumoniae* Ecl8 genomic DNA by using primers (introduced restriction sites underlined): *kvrA* full length *Bam*HI FW (5'-AAAGGATCCCGGCAATCCGGATGTGTTAAGAC-3') and *kvrA* full length *Sall* RV (5'-AAAGTCGACGGAGGGTGAAAAAGGCCCGGATTA-3'). The PCR product was digested and inserted to pUBYT (25) cut with *Bam*HI and *Sall* to generate pUBYT::*kvrA*. The recombinant plasmid was then transferred into FQ3 M1 cells by electroporation. The transformants were selected using kanamycin (50 µg.mL⁻¹) and the presence of plasmids was confirmed by PCR using primers pUBYT check FW (5'-GCAAGAAGGTGATGAATCTACA-3') and pUBYT check RV (5'-GTGGCAGCAGCCAACTCA-3'). Complementation of FQ3 M1 with pUBYT::*kvrA* showed that the MICs of cefoxitin and cefuroxime reduced, but again not to a value as low as against FQ3. This confirmed the result of the gene inactivation experiment that *kvrA* loss alone is not the sole determinant of the cephalosporin resistant phenotype expressed by FQ3 M1 (**Table 3**).

Given that inactivation of either *kvrA* or *nlpD* in FQ3 reduced cephalosporin susceptibility, we performed LC-MS/MS envelope proteomics for these mutants versus FQ3 as above, which revealed that mutation in *kvrA* caused a reduction in OmpF (OmpK35) and OmpC (OmpK36) porin levels in FQ3, to the same extent as seen in FQ3 M1. Mutation in *nlpD*, despite altering cephalosporin MIC, did not (**Fig. 1 A, B**). Because FQ3 is derived from Ecl8, a laboratory strain, and because FQ3 carries mutations that increase efflux pump production (9), we wanted to test the impact of *kvrA* inactivation in a wild-type clinical isolate. To do this, we insertionally inactivated *kvrA* (as above) in the susceptible *K. pneumoniae* clinical isolate S17, which has wild-type envelope permeability (26) and showed by LC-MS/MS that OmpF and OmpC levels fell in this mutant relative to S17, as seen in FQ3. Porin abundance did not change upon *nlpD* inactivation in S17, also as seen in FQ3 (**Fig. 1 C, D**).

β-Lactamase inhibitors such as clavulanic acid, tazobactam and sulbactam have been successful in overcoming resistance to penicillin derivatives, e.g. amoxicillin, piperacillin and ticarcillin in Enterobacteriaceae. However, inhibitor/penicillin combinations are not clinically useful against KPC, CTX-M, OXA-48-like or AmpC producing Enterobacteriaceae isolates, or those producing metallo-β-lactamases (27). This has led to the development of new β-lactam/β-lactamase inhibitor combinations, and one recently licenced for clinical use is meropenem/vaborbactam (28). Vaborbactam is a serine β-lactamases inhibitor based on a cyclic boronic acid pharmacophore. It has potent in vitro activity against class A β-lactamases, particularly KPC, and it can restore the activity of meropenem against KPC-producing Enterobacteriaceae (29-31).

Meropenem/vaborbactam resistance in KPC-producing *K. pneumoniae* has been shown to occur by loss of function mutation in *ompK36*, which encodes is the primary porin for meropenem entry (32,33). We therefore wanted to test the impact of OmpK36 porin reduction seen following inactivation of *kvrA* in *K. pneumoniae* S17 (**Fig. 1C**) on meropenem/vaborbactam susceptibility when the mutant produces KPC. To investigate this, we used pUBYT::*bla*_{KPC-3} (25) to transform *K. pneumoniae* S17, S17Δ*kvrA* and S17Δ*ompK36* (as a control). As expected, due to carriage of KPC, all transformants were resistant to meropenem. Addition of 8 μg.mL⁻¹ vaborbactam (8 μg.mL⁻¹) reduced the meropenem MIC against S17 well into the susceptible range. In contrast, meropenem/vaborbactam MICs against the *kvrA* and *ompK36* mutants were 1 μg.mL⁻¹ (four doublings higher than against S17) and 32 μg.mL⁻¹ respectively (**Table 4**). Hence, even in an otherwise wild-type KPC-producing clinical *K. pneumoniae* isolate (26), OmpK35/OmpK36 downregulation caused solely by *kvrA* mutation is enough to reduce meropenem/varborbactam susceptibility.

In conclusion, we report here two loss of function mutations in genes previously not known to affect antimicrobial susceptibility in *K. pneumoniae*. NlpD ("new lipoprotein D") is conserved across Gram-negative bacteria, with essential roles in virulence, e.g. in *Yersinia pestis* (34). In *E. coli* it is recruited to the division site where it targets the activity of the peptidoglycan amidase AmiC, to which it binds. Loss of NlpD in *E. coli* is known to delay the onset of cell lysis after treatment with ampicillin because peptidoglycan breakdown by AmiC is less targeted to the division site (35,36). This provides a clear rationale for why disruption of *nlpD* reduces β-lactam susceptibility in *K. pneumoniae* (**Table 1**), but its role as a mediator of cefuroxime resistance has not previously been suspected.

We also report that inactivation of *kvrA* causes cefuroxime resistance in *K. pneumoniae*, but more importantly, it causes reduced susceptibility meropenem/vaborbactam, even in an otherwise wild-type *K. pneumoniae* clinical isolate, transformed to express *bla*_{KPC-3} from its native promoter in a low copy number vector (25). We show that cefuroxime resistance and reduced meropenem/vaborbactam susceptibility in a *kvrA* mutant is associated with OmpK35/OmpK36 downregulation. This is reminiscent of OmpR mutations in *E. coli*, which reduce OmpC/OmpF production and can also affect antimicrobial susceptibility (37).

KvrA is a MarR-family transcriptional repressor. Importantly, we found that YdhJ is upregulated 45-fold ($p=0.002$, $n=3$) and >100-fold ($p<0.0001$, $n=3$) according to proteomics following disruption of *kvrA* in *K. pneumoniae* S17 and FQ3, respectively. YdhJ is encoded within a putative efflux pump operon adjacent to *kvrA* on the chromosome. Expression of the homologue of this *ydhIJK* operon in *E. coli* is directly repressed by SlyA (38), which is

encoded upstream of *ydhIJK*, in an almost identical arrangement as *kvrA* and *ydhIJK* in *K. pneumoniae*. Therefore, the *ydhIJK* operon is likely to be the direct repressive target of KvrA in this species, with its wider activatory effects being indirect. Similar characterised MarR-family repressors such as SlyA also tend to have local direct repressive effects, but cause activation of gene expression at some promoters indirectly by blocking the repressive activity of H-NS at those promoters (39). Since H-NS is known to have a repressive effect on porin production in *E. coli* (40) it may well be that increased repressive activity of H-NS in the absence of KvrA is the explanation for OmpK35/OmpK36 downregulation seen in *K. pneumoniae*.

Disruption of *kvrA* also causes downregulation of key capsule biosynthesis genes, e.g. *galF*, *manC* and *wzi* in some *K. pneumoniae* strains (20). We found using proteomics that Wzi was downregulated a marginal 0.82-fold ($p=0.03$, $n=3$) upon disruption of *kvrA* in isolate S17 but not the GalF or ManC and none of these proteins were downregulated in FQ3Δ*kvrA* versus FQ3. However, it is known that *kvrA* loss does not reduce capsule production in all strains, and nor does it attenuate the virulence of all strains in a mouse infection model (20). Among 455 isolates of *K. pneumoniae* from NCBI database, we found 9 isolates (Genbank accession numbers CP037927, LR134162, CP032175, CP018056, CP003200, LR588409, CP044039, CP043670, CP043669) where *kvrA* was mutated in a way predicted to result in a truncated and presumably non-functional KvrA. One key example is the KPC-2 and CTX-M-14 producing carbapenem resistant human sputum isolate HS11286 (41, 42). This confirms that *kvrA* mutants are present in human clinical samples.

Acknowledgments

This work was funded by grant MR/S004769/1 to M.B.A. from the Antimicrobial Resistance Cross Council Initiative supported by the seven United Kingdom research councils and the National Institute for Health Research. Genome sequencing was provided by MicrobesNG (<http://www.microbesng.uk/>), which is supported by the BBSRC (grant number BB/L024209/1). W.A.K.W.N.I. was funded by a postgraduate scholarship from the Malaysian Ministry of Education. We are grateful to Dr Kate Heesom, School of Biochemistry, University of Bristol for performing the proteomics analysis and Melissa Rose Bennett, School of Cellular & Molecular Medicine, University of Bristol for assistance in selecting FQ3 M1.

We declare no conflicts of interest.

204 Figure Legends

205 **Figure 1. Normalised abundance of OmpK35 and OmpK36 porins in *K. pneumoniae*** 206 ***kvrA* and *nlpD* mutants.**

207 OmpC (OmpK36) and OmpF (OmpK35) abundance was measured using LC-MS/MS and
208 normalised to the abundance of OmpA, to control for protein loading. Data presents mean $\pm$
209 standard error of the mean, $n=3$. Asterisk (*) indicates statistically significant differences
210 from the parental strains by t-test ($p<0.05$). (A) OmpC to OmpA protein ratio and (B) OmpF
211 to OmpA protein ratio in FQ3 and its mutant derivatives. (C) OmpC to OmpA protein ratio
212 and (D) OmpF to OmpA protein ratio in clinical isolate S17 and its mutant derivatives.

213 Tables

214

215 **Table 1: Inhibition zone diameters (mm) for antimicrobials against *K. pneumoniae* FQ3**
216 **and cefuroxime resistant mutant FQ3 M1.**

Antimicrobial	Parental strain, FQ3	FQ3 M1
Meropenem	29	26
Ertapenem	28	23
Imipenem	28	25
Doripenem	27	26
Aztreonam	32	31
Cefepime	30	26
Ceftazidime	28	26
Cefotaxime	28	25
Ceftriaxone	30	27
Ceftizoxime	33	30
Cefoperazone	28	24
Cefotetan	25	21
Cefoxitin	19	10
Cefuroxime	19	13
Cephalexin	18	10
Ciprofloxacin	11	11
Norfloxacin	8	6
Ofloxacin	8	6
Levofloxacin	11	9
Chloramphenicol	8	6
Minocycline	13	12
Amikacin	26	25
Gentamicin	25	23

217

218 Values reported are the means of three repetitions rounded to the nearest integer for the
219 diameter of the growth inhibition zone across each antimicrobial disc (mm). Shading
220 indicates resistance according to susceptibility breakpoints set by the CLSI (11).

221 **Table 2: Significant changes in envelope protein abundance seen in *K. pneumoniae* mutant FQ3 M1 vs parent strain FQ3**

Accession	Description	Abundance FQ3 (1)	Abundance FQ3 (2)	Abundance FQ3 (3)	Abundance FQ3 M1 (1)	Abundance FQ3 M1 (2)	Abundance FQ3 M1 (3)	T-test	Fold change
A6T518	Phosphoheptose isomerase, GmhA	-	-	-	1.18E+08	2.05E+07	2.02E+07	<0.0005	>20
A6T720	Aspartate aminotransferase, AspC	-	-	-	2.11E+07	1.92E+07	2.27E+07	<0.0005	>20
A6TBN4	ATP-binding component of methyl- galactoside transporter, MglA	-	-	-	2.64E+07	2.11E+07	3.40E+07	<0.0005	>20
A6TF45	sn-glycerol-3-phosphate dehydrogenase, GlpD	3.10E+07	1.21E+07	3.24E+07	2.37E+08	1.24E+09	1.72E+09	0.004	42.43
A6T5Q5	Putative outer membrane protein	4.62E+08	3.06E+08	4.48E+08	1.61E+09	1.85E+09	1.51E+09	<0.0005	4.09
A6TBM3	Putative channel/filament proteins, YohG	2.93E+08	2.57E+08	4.77E+08	9.04E+08	1.04E+09	1.31E+09	<0.0005	3.16
A6T4Y7	Acetyl-coenzyme A carboxylase carboxyl transferase, AccA	1.24E+08	8.31E+08	4.06E+08	1.15E+09	7.38E+08	9.36E+08	0.005	2.07
A6T8N5	Putative uncharacterized protein, YdgH	6.65E+08	5.22E+08	8.53E+08	3.69E+08	3.61E+08	3.44E+08	0.001	0.53
A6T721	OmpF porin (OmpK35)	1.19E+10	7.32E+09	7.82E+09	2.89E+09	3.97E+09	3.01E+09	0.001	0.36
A6TBT2	OmpC porin (OmpK36)	3.49E+10	3.13E+10	3.41E+10	1.12E+10	1.31E+10	1.00E+10	<0.0005	0.34
A6TD34	Lipoprotein, NlpD	9.15E+08	7.51E+08	1.14E+09	2.64E+08	1.68E+08	3.13E+08	<0.0005	0.27
A6T4Y4	Lipid-A-disaccharide synthase, LpxB	6.06E+07	5.19E+07	1.02E+08	-	-	-	<0.0005	<0.005
A6T9Z3	Putative multidrug resistance protein, YdhJ	7.23E+07	6.50E+07	9.18E+07	-	-	-	<0.0005	<0.005
A6TBM5	Putative cellobiose-specific PTS permease	2.83E+07	1.66E+07	3.57E+07	-	-	-	<0.0005	<0.005
A6TEA5	Putative glycerol dehydrogenase, DhaD	5.00E+07	2.28E+08	2.51E+08	-	-	-	<0.0005	<0.005

222 Strains were grown in nutrient broth and raw abundance data are provided for three biological replicates of parent (FQ3) and mutant (FQ3 M1).

223 Analysis was as described in (9) and proteins listed are those with significantly different abundance in FQ3 M1 versus FQ3.

224 **Table 3 MICs ($\mu\text{g.mL}^{-1}$) of cephalosporins against *K. pneumoniae* Ecl8 FQ3 and mutant**
 225 **derivatives.**

	Cefuroxime MIC	Cefoxitin MIC
FQ3	8	8
FQ3 $\Delta dhaR$	8	8
FQ3 $\Delta ompK35$	8	8
FQ3 $\Delta kvrA$	16	32
FQ3 $\Delta nlpD$	32	32
FQ3 $\Delta ompK36$	32	32
FQ3 M1	64	64
FQ3 M1(pUBYT)	32	64
FQ3 M1(pUBYT:: <i>kvrA</i>)	16	16

226

227 The CLSI susceptible and resistance breakpoints (11) for cefuroxime and cefoxitin are ≤ 8
 228 and $\geq 32 \mu\text{g.mL}^{-1}$.

229 **Table 4 MICs ($\mu\text{g.mL}^{-1}$) of meropenem against *K. pneumoniae* clinical isolate S17 and**
 230 **mutant derivatives measured with and without 8 $\mu\text{g.mL}^{-1}$ of vaborbactam.**

231


	Meropenem MIC	Meropenem/Vaborbactam MIC
S17/pKPC-3	128	0.0625/8
S17 $\Delta ompK36$ /pKPC-3	>256	32/8
S17 $\Delta kvrA$ /pKPC-3	256	1/8

232


233 The CLSI susceptible and resistance breakpoints (11) for meropenem are ≤ 1 and ≥ 4 $\mu\text{g.mL}^{-1}$
 234 in the absence and ≤ 4 and ≥ 16 $\mu\text{g.mL}^{-1}$ in the presence of 8 $\mu\text{g.mL}^{-1}$ vaborbactam.

235 **Figure 1**

236 **A**



B




237


238

239

240 **C**



D



241

References

1. Grundmann H, Glasner C, Albiger B, Aanensen DM, Tomlinson CT, Andrasević AT, Cantón R, Carmeli Y, Friedrich AW, Giske CG, Glupczynski Y, Gniadkowski M, Livermore DM, Nordmann P, Poirel L, Rossolini GM, Seifert H, Vatopoulos A, Walsh T, Woodford N, Monnet DL. 2017. Occurrence of carbapenemase-producing *Klebsiella pneumoniae* and *Escherichia coli* in the European survey of carbapenemase-producing Enterobacteriaceae (EuSCAPE): a prospective, multinational study. *Lancet Infect Dis* 17:153–163.
2. Walsh TR. 2010. Emerging carbapenemases: a global perspective. *Int J Antimicrob Agents* 36:S8–14.
3. Queenan AM, Bush K. Carbapenemases: the versatile β -lactamases. 2007. *Clin Microbiol Rev* 20:440–458.
4. Lee C-H, Chu C, Liu J-W, Chen Y-S, Chiu C-J, Su L-H. 2007. Collateral damage of flomoxef therapy: in vivo development of porin deficiency and acquisition of *bla*_{DHA-1} leading to ertapenem resistance in a clinical isolate of *Klebsiella pneumoniae* producing CTX-M-3 and SHV-5 β -lactamases. *J Antimicrob Chemother* 60:410–413.
5. Nordmann P, Dortet L, Poirel L. 2012. Carbapenem resistance in Enterobacteriaceae: here is the storm! *Trends Mol Med* 18:263–272.
6. Pitout JDD, Nordmann P, Poirel L. 2015. Carbapenemase-Producing *Klebsiella pneumoniae*, a Key Pathogen Set for Global Nosocomial Dominance. *Antimicrob Agents Chemother* 59:5873–5884.
7. Papp-Wallace KM, Endimiani A, Taracila MA, Bonomo RA. 2011. Carbapenems: past, present, and future. *Antimicrob Agents Chemother* 55:4943–4960.
8. Yan J, Pu S, Jia X, Xu X, Yang S, Shi J, Sun S, Zhang L. 2017. Multidrug Resistance Mechanisms of Carbapenem Resistant *Klebsiella pneumoniae* Strains Isolated in Chongqing, China. *Ann Lab Med* 37:398–407.
9. Wan Nur Ismah WAK, Takebayashi Y, Findlay J, Heesom KJ, Avison MB. 2018. Impact of OqxR loss of function on the envelope proteome of *Klebsiella pneumoniae* and susceptibility to antimicrobials. *J Antimicrob Chemother* 73:2990-2996.
10. Clinical and Laboratory Standards Institute. 2006. M2-A9. Performance standards for antimicrobial disc susceptibility tests; approved standard, 9th ed. Clinical and Laboratory Standards Institute, Wayne, PA.
11. Clinical and Laboratory Standards Institute. 2019. M100-S29. Performance standards for antimicrobial susceptibility testing; twenty-ninth informational supplement. An informational supplement for global application developed through the Clinical and Laboratory Standards Institute consensus process. Clinical and Laboratory Standards

278 Institute, Wayne, PA.

279 12. Bolger AM, Lohse M, Usadel B. 2014. Trimmomatic: a flexible trimmer for Illumina
280 sequence data. *Bioinformatics* 30:2114–2120.

281 13. Darling AE, Mau B, Perna NT, Batzoglou S, Zhong Y. 2010. progressiveMauve: multiple
282 genome alignment with gene gain, loss and rearrangement. *PLoS One* 5:e111147.

283 14. Cai SJ, Inouye M. 2002. EnvZ-OmpR interaction and osmoregulation in *Escherichia coli*.
284 *J Biol Chem* 277:24155–24161.

285 15. Lange R, Hengge-Aronis R. 1994. The *nlpD* gene is located in an operon with *rpoS* on
286 the *Escherichia coli* chromosome and encodes a novel lipoprotein with a potential
287 function in cell wall formation. *Mol Microbiol* 13:733–743.

288 16. Ichikawa JK, Li C, Fu J, Clarke S. 1994. A gene at 59 minutes on the *Escherichia coli*
289 chromosome encodes a lipoprotein with unusual amino acid repeat sequences. *J*
290 *Bacteriol* 176:1630–1638.

291 17. Tsang M-J, Yakhnina AA, Bernhardt TG. 2017. NlpD links cell wall remodeling and outer
292 membrane invagination during cytokinesis in *Escherichia coli*. *PLOS Genet*
293 13:e1006888.

294 18. Martins-Pinheiro M, Lima WC, Asif H, Oller CA, Menck CFM. 2016. Evolutionary and
295 Functional Relationships of the *dha* Regulon by Genomic Context Analysis. *PLoS One*
296 11:e0150772.

297 19. Zheng P, Wereath K, Sun J, van den Heuvel J, Zeng A-P. 2006. Overexpression of
298 genes of the *dha* regulon and its effects on cell growth, glycerol fermentation to 1,3-
299 propanediol and plasmid stability in *Klebsiella pneumoniae*. *Process Biochem* 41:2160–
300 2169.

301 20. Palacios M, Miner TA, Frederick DR, Sepulveda VE, Quinn JD, Walker KA, Miller VL.
302 2018. Identification of Two Regulators of Virulence That Are Conserved in *Klebsiella*
303 *pneumoniae* Classical and Hypervirulent Strains. *MBio* 9. pii:e01443-18.

304 21. Dorman MJ, Feltwell T, Goulding DA, Parkhill J, Short FL. 2018. The Capsule Regulatory
305 Network of *Klebsiella pneumoniae* Defined by density-TraDISort. *MBio*. 9. pii:e01863-18.

306 22. Walker KA, Miner TA, Palacios M, Trzilova D, Frederick DR, Broberg CA, Sepúlveda VE,
307 Quinn JD, Miller VL. 2019. A *Klebsiella pneumoniae* Regulatory Mutant Has Reduced
308 Capsule Expression but Retains Hypermucoviscosity. *MBio* 10. pii:e00089-19.

309 23. Alexeyev MF. 1999. The pKNOCK series of broad-host-range mobilizable suicide
310 vectors for gene knockout and targeted DNA insertion into the chromosome of gram-
311 negative bacteria. *BioTechniques* 26:824-828.

312 24. Clinical and Laboratory Standards Institute. 2015. M07-A10. Methods for dilution
313 antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard,
314 10th ed. Clinical and Laboratory Standards Institute, Wayne, PA.

25. Takebayashi Y, Wan Nur Ismah WHK, Findlay J, Heesom KJ, Zhang J, Williams OM, MacGowan AP, Avison MB. 2017. Prediction of cephalosporin and carbapenem susceptibility in multi-drug resistant Gram-negative bacteria using liquid chromatography-tandem mass spectrometry. *BioRxiv* 138594; doi: <https://doi.org/10.1101/138594>.
26. Wan Nur Ismah WAK, Takebayashi Y, Findlay J, Heesom KJ, Jiménez-Castellanos JC, Zhang J, Graham L, Bowker K, Williams OM, MacGowan AP, Avison MB. 2018. Prediction of Fluoroquinolone Susceptibility Directly from Whole-Genome Sequence Data by Using Liquid Chromatography-Tandem Mass Spectrometry To Identify Mutant Genotypes. *Antimicrob Agents Chemother* 62 pii:e01814-17.
27. Drawz SM, Bonomo RA. 2010. Three decades of β -lactamase inhibitors. *Clin Microbiol Rev* 23:160–201.
28. Hecker SJ, Reddy KR, Totrov M, Hirst GC, Lomovskaya O, Griffith DC, King P, Tsivkovski R, Sun D, Sabet M, Tarazi Z, Clifton MC, Atkins K, Raymond A, Potts KT, Abendroth J, Boyer SH, Loutit JS, Morgan EE, Durso S, Dudley MN. 2015. Discovery of a Cyclic Boronic Acid β -Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases. *J Med Chem* 8: 3682–3692.
29. Zhanel GG, Lawrence CK, Adam H, Schweizer F, Zelenitsky S, Zhanel M, Lagacé-Wiens PRS, Walkty A, Denisuik A, Golden A, Gin AS, Hoban DJ, Lynch JP, Karlowsky JA. 2018. Imipenem–Relebactam and Meropenem–Vaborbactam: Two Novel Carbapenem- β -Lactamase Inhibitor Combinations. *Drugs* 78:65–98.
30. Hackel MA, Lomovskaya O, Dudley MN, Karlowsky JA, Sahm DF. 2018. In Vitro Activity of Meropenem-Vaborbactam against Clinical Isolates of KPC-Positive Enterobacteriaceae. *Antimicrob Agents Chemother* 62:e01904-17.
31. Christina S, Jorgensen J, Rybak MJ. 2018. Meropenem and Vaborbactam: Stepping up the Battle against Carbapenem-resistant Enterobacteriaceae. *Pharmacotherapy* 38:444–461.
32. Lomovskaya O, Sun D, Rubio-Aparicio D, Nelson K, Tsivkovski R, Griffith DC, Dudley MN. 2017. Vaborbactam: Spectrum of β -Lactamase Inhibition and Impact of Resistance Mechanisms on Activity in Enterobacteriaceae. *Antimicrob Agents Chemother* 61:e01443-17.
33. Findlay J, Hamouda A, Dancer SJJ, Amyes SGB. 2012. Rapid acquisition of decreased carbapenem susceptibility in a strain of *Klebsiella pneumoniae* arising during meropenem therapy. *Clin Microbiol Infect* 18:140–146.
34. Tidhar A, Flashner Y, Cohen S, Levi Y, Zauberman A, Gur D, Aftalion M, Elhanany E, Zvi A, Shafferman A, Mamroud E. 2009. The NlpD lipoprotein is a novel *Yersinia pestis* virulence factor essential for the development of plague. *PLoS One*. 4:e7023.
35. Uehara T, Dinh T, Bernhardt TG. 2009. LytM-domain factors are required for daughter

cell separation and rapid ampicillin-induced lysis in *Escherichia coli*. J Bacteriol. 191:5094-5107.

36. Uehara T, Parzych KR, Dinh T, Bernhardt TG. 2010. Daughter cell separation is controlled by cytokinetic ring-activated cell wall hydrolysis. EMBO J. 29:1412-1422.

37. Dupont H, Choinier P, Roche D, Adiba S, Sookdeb M, Branger C, Denamur E, Mammeri H. 2017. Structural Alteration of OmpR as a Source of Ertapenem Resistance in a CTX-M-15-Producing *Escherichia coli* O25b:H4 Sequence Type 131 Clinical Isolate. Antimicrob Agents Chemother. 61. pii:e00014-17.

38. Curran TD, Abacha F, Hibberd SP, Rolfe MD, Lacey MM, Green J. 2017. Identification of new members of the *Escherichia coli* K-12 MG1655 SlyA regulon. Microbiology 163:400-409.

39. Colgan AM, Kröger C, Diard M, Hardt WD, Puente JL, Sivasankaran SK, Hokamp K, Hinton JC. 2016. The Impact of 18 Ancestral and Horizontally-Acquired Regulatory Proteins upon the Transcriptome and sRNA Landscape of *Salmonella enterica* serovar Typhimurium. PLoS Genet. 12:e1006258.

40. De la Cruz MA, Calva E. 2010. The complexities of porin genetic regulation. J Mol Microbiol Biotechnol 18:24-36.

41. Liu P, Li P, Jiang X, Bi D, Xie Y, Tai C, Deng Z, Rajakumar K, Ou HY. 2012. Complete genome sequence of *Klebsiella pneumoniae* subsp. *pneumoniae* HS11286, a multidrug-resistant strain isolated from human sputum. J Bacteriol 194:1841-1842.

42. Bi D, Jiang X, Sheng ZK, Ngmenterebo D, Tai C, Wang M, Deng Z, Rajakumar K, Ou HY. 2015. Mapping the resistance-associated mobilome of a carbapenem-resistant *Klebsiella pneumoniae* strain reveals insights into factors shaping these regions and facilitates generation of a 'resistance-disarmed' model organism. J Antimicrob Chemother. 70:2770-2774.